High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.
Microtubule-associated protein 7 (MAP7) plays an important role in cancer cells. In this study, we identified the prognostic significance of MAP7 expression in cytogenetically normal acute myeloid leukemia (CN-AML) patients (aged <60 years) based on several microarray datasets. In the first group (n = 129), high MAP7 expression (MAP7high) was associated with adverse overall survival (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low MAP7 expression (MAP7low). In addition, the prognostic significance of MAP7 was confirmed by European Leukemia Net (ELN) intermediate-I genetic categories and multivariable analysis. In the second independent group of CN-AML patients (aged <60 years), MAP7highwas also associated with adverse OS (n = 88, OS; P = 0.00811). To understand the inherent mechanisms of MAP7's prognosis, we investigated genome-wide gene/microRNA expression signatures associated with MAP7 expression. Several known oncogenic genes/microRNAs and anti-oncogenic genes/microRNAs were disordered in MAP7highCN-AML patients. In conclusion, MAP7highis an adverse prognostic biomarker for CN-AML, which may be attributed to the distinctive genome-wide gene/microRNA expression and related cell signaling pathways.
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.|Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China.|Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221002, China.
Lin
L
Fu
Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Huaping
H
Fu
Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.
Lei
L
Zhou
College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, 163319, China.
Keman
K
Xu
Department of Medicine, William Beaumont Hospital, Royal Oak, MI, 48073, USA.
Yifan
Y
Pang
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Kai
K
Hu
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Jing
J
Wang
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Lei
L
Tian
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Yuanyuan
Y
Liu
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Jijun
J
Wang
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Hongmei
H
Jing
Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.
Wenrong
W
Huang
Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Xiaoyan
X
Ke
Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China.
Jinlong
J
Shi
FEBS J. 2014 Sep;281(17):3904-19
25041463
Leuk Res. 2015 Dec;39(12):1389-95
26340914
Oncotarget. 2016 Mar 29;7(13):15828-39
26910834
Cancer Cell. 2015 Sep 14;28(3):329-42
26373280
J Med Genet. 2006 Apr;43(4):e14
16582076
Blood. 2010 Dec 16;116(25):5660-9
20841507
Mol Cancer Ther. 2014 Dec;13(12):3185-97
25319390
Oncotarget. 2015 Mar 10;6(7):5299-309
25779662
Oncotarget. 2015 Aug 7;6(22):19102-17
26036258
Cancer Cell Int. 2013 Nov 05;13(1):110
24191888
Oncotarget. 2015 Oct 27;6(33):34968-78
26392416
Leuk Res. 2011 Dec;35(12):1585-90
21899885
Leukemia. 2015 Mar;29(3):567-75
25204569
J Clin Oncol. 2013 Mar 20;31(9):1172-81
23382473
Oncotarget. 2015 Apr 10;6(10):8144-54
25924238
Blood. 2012 Sep 6;120(10):2118-26
22815426
Oncotarget. 2016 Jan 19;7(3):2585-95
26506237
Nat Rev Cancer. 2010 May;10(5):361-71
20357775
Leuk Lymphoma. 2014 Dec;55(12):2817-21
24559289
Oncogene. 2011 Aug 4;30(31):3416-28
21399664
Clin Cancer Res. 2007 May 15;13(10):2849-54
17504982
Neoplasma. 2015 ;62(6):949-58
26458312
Turk J Haematol. 2013 Jun;30(2):157-62
24385779
Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8
12229925
Nat Commun. 2012 Feb 21;3:688
22353710
Tumour Biol. 2016 Mar;37(3):3749-56
26468017
Cancer Gene Ther. 2014 Sep;21(9):397-404
25213664
Int J Cancer. 2013 Aug 1;133(3):579-89
23341351
Leukemia. 2016 Feb;30(2):274-84
26376228
Br J Cancer. 2013 Jun 11;108(11):2304-11
23695020
Eur J Haematol. 2010 Apr;84(4):298-303
20002157
Pancreatology. 2009;9(3):293-301
19407485
J Clin Invest. 2013 Sep;123(9):3876-88
23979164
N Engl J Med. 2008 May 1;358(18):1919-28
18450603
Sci Rep. 2015 Nov 06;5:16229
26542173
Leuk Res. 2016 Jan;40:60-7
26563595
Blood. 2012 Sep 6;120(10):2064-75
22786876
Blood. 2001 Dec 1;98(12):3413-20
11719382
Int J Hematol. 2015 Sep;102(3):296-303
26134365
PLoS One. 2012;7(12):e50895
23236401
Haematologica. 2015 Jul;100(7):905-13
25911551
Haematologica. 2013 Mar;98(3):424-7
23144197
Cell Death Dis. 2014 Dec 11;5:e1564
25501825
Blood Rev. 2004 Jun;18(2):115-36
15010150
Biochem Biophys Res Commun. 2015 May 8;460(3):670-7
25817794
Blood. 2011 Sep 8;118(10):2857-67
21753187
Oncotarget. 2012 Nov;3(11):1370-85
23211491
Int J Oncol. 2008 Sep;33(3):579-84
18695889